Pancreatic Cancer Research Team

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.pcrt.org

Clinical Trials

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2

Conditions: Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Pancreatic Neoplasms

Interventions: Drug: PEGPH20
Biological: Pembrolizumab

First Posted Date: 2018-08-16

Last Posted Date: 2019-05-07

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 35

Registration Number: NCT03634332

Locations: 🇺🇸
Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
🇺🇸
University of Washington--Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 2 locations

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Phase 2

Withdrawn

Conditions: Resectable Pancreatic Cancer

Interventions: Drug: NGC-Triple regimen

First Posted Date: 2018-01-08

Last Posted Date: 2019-05-07

Lead Sponsor: Pancreatic Cancer Research Team

Registration Number: NCT03392571

Project Survival-Prospective Biomarker Discovery

Conditions: Pancreatic Cancer
Pancreatitis
Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Pancreatic Neoplasms

First Posted Date: 2016-05-24

Last Posted Date: 2019-04-16

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 436

Registration Number: NCT02781012

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸
Mercy Health - St. Mary's, Grand Rapids, Michigan, United States

and more 3 locations

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Phase 1

Completed

Conditions: Stage IV Pancreatic Cancer

Interventions: Drug: nab-paclitaxel
Drug: Cisplatin
Drug: gemcitabine

First Posted Date: 2013-07-09

Last Posted Date: 2019-05-29

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 25

Registration Number: NCT01893801

Locations: 🇺🇸
Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
🇺🇸
Scottsdale Health Care, Scottsdale, Arizona, United States
🇺🇸
Vita Medical Associates, PC, Bethlehem, Pennsylvania, United States

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Stage IV Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: nab-paclitaxel
Drug: FOLFIRINOX
Genetic: Immunohistochemistry (IHC) Analysis
Drug: Metformin
Drug: mFOLFIRI

First Posted Date: 2011-12-08

Last Posted Date: 2016-08-18

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 60

Registration Number: NCT01488552

Locations: 🇺🇸
Evergreen Hematology and Oncology, Spokane, Washington, United States
🇺🇸
Disney Family Cancer Center, Burbank, California, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

and more 2 locations

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Phase 2

Completed

Conditions: Resectable Pancreatic Cancer

Interventions: Drug: Gemcitabine and Abraxane

First Posted Date: 2011-02-17

Last Posted Date: 2015-06-17

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 25

Registration Number: NCT01298011

Locations: 🇺🇸
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
St Mary's / Trinity Health Care, Grand Rapids, Michigan, United States
🇺🇸
Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States

and more 1 locations

Pancreatic Cancer Serum and DNA Repository

Completed

Conditions: Pancreas Cancer

First Posted Date: 2006-02-24

Last Posted Date: 2013-05-01

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 690

Registration Number: NCT00296114

Locations: 🇺🇸
University of Arizona/Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins, Baltimore, Maryland, United States

and more 7 locations

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Neoplasm

Interventions: Drug: PTK787/ZK222584

First Posted Date: 2005-09-26

Last Posted Date: 2012-05-09

Lead Sponsor: Pancreatic Cancer Research Team

Target Recruit Count: 67

Registration Number: NCT00226005

Locations: 🇺🇸
Tower Hematology Oncology Medical Group, Beverly Hills, California, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States

and more 4 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy